CD19 and mantle cell lymphoma: To deal with the failure related to target loss, autologous anti-CD20 CAR-T cell therapy (NCT03277729), but also bispecific anti-CD19/CD20 CAR-T cells, are under investigation in MCL (NCT04007029, NCT04186520).